According to new research, radiation therapy administered before surgery rarely produces favorable responses in patients with retroperitoneal sarcoma (RPS), a rare and aggressive cancer that forms in ...
Early results from preclinical studies and a clinical trial led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center and Stanford Medicine suggest that combining targeted radiation ...
Real-world outcomes of biomarker-intended pembrolizumab use in soft tissue sarcomas. Phase 3, multicenter, randomized, controlled open-label study: Efficacy and safety of M701 (EpCAM×CD3 bispecific ...
Ewing sarcoma is a rare, aggressive cancer that primarily strikes children and adolescents, yet it can present in infants, where it is exceptionally uncommon. U.S. registry data show an incidence of ...
Public sarcoma awareness brought about by Sarcoma Awareness Month has led to research & treatment advances, & potentially fewer misdiagnoses.
Clinical Impact of Integrating RNA-Based Next-Generation Sequencing Into the Diagnostic Evaluation of Soft Tissue Sarcomas: Insights From a Single-Center Multidisciplinary Workflow We conducted a ...
Transitioning from accelerated to traditional status, the FDA's decision expands eligibility for the first solid-tumor engineered T cell therapy to include adolescents aged 12 and older.
Only one retroperitoneal sarcoma (RPS) patient out of 22 achieved meaningful tumor shrinkage with pre-surgical radiation, while over 75% of the sample saw no significant change and 18% experienced ...
A triple-drug regimen combining two immunotherapy agents with radiation before surgery appears to activate immune defenses against aggressive soft tissue sarcomas, based on early phase II data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results